Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer

• Main Authors: Collins, Denis M., Conlon, Neil T., Kannan, Srinivasaraghavan, Verma, Chandra Shekhar, Eli, Lisa D., Lalani, Alshad S., Crown, John
• 其他作者: School of Biological Sciences
• 格式: Article
• 語言: English
• 出版: 2020
• 主題: Science::Biological sciences; Tyrosine Kinase Inhibitors; Lapatinib
• 在線閱讀: https://hdl.handle.net/10356/142754

An estimated 15-20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and neratinib, have been approved for the treatment of HER2-positive (HER2+) breast cancer. Lapatinib, a reversible epidermal g...